Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affinia Therapeutics receives FDA orphan drug designation for AFTX-201
AFTX-201 uses a functional BAG3 transgene and Affinia’s proprietary capsid for targeted, lower-dose heart delivery. Credit: Umaporn Kensila/Shutterstock.com.
AFTX-201 uses a functional BAG3 transgene and Affinia’s proprietary capsid for targeted, lower-dose heart delivery. Credit: Umaporn Kensila/Shutterstock.com.